CG Oncology has taken the ribbon for the first biotech initial public offering (IPO) of the new year and its $380 million raise – which far outstrips the proceeds forecast
The combination of Bristol-Myers Squibb’s Opdivo and Yervoy cancer immunotherapies is on track for approval as a first-line therapy for patients with a particular form of
CG Oncology is the latest biotech to take a look at a share listing in the US, aiming to raise around $180 million in the process, in another sign of a possible recovery i
Roche has been given EU approval for a new formulation of its cancer immunotherapy Tecentriq that aims to make dosing easier for patients, nurses, and physicians.
MSD’s 2023 run of pipeline-building deals looks like it could continue into this year, with reports already emerging that the company is in talks to buy Harpoon Therapeuti
AbbVie has signed a wide-ranging collaboration with Umoja Biopharma in the area of ‘in situ’ or in vivo cell therapy, an emerging strategy that does away with the need to